HRP20020007A2 - Vitamin d3 analogs - Google Patents

Vitamin d3 analogs Download PDF

Info

Publication number
HRP20020007A2
HRP20020007A2 HR20020007A HRP20020007A HRP20020007A2 HR P20020007 A2 HRP20020007 A2 HR P20020007A2 HR 20020007 A HR20020007 A HR 20020007A HR P20020007 A HRP20020007 A HR P20020007A HR P20020007 A2 HRP20020007 A2 HR P20020007A2
Authority
HR
Croatia
Prior art keywords
formula
trans
compounds
image
cells
Prior art date
Application number
HR20020007A
Other languages
English (en)
Croatian (hr)
Inventor
Andrew David Batcho
Bernard Michael Hennessy
Milan Radoje Uskokovic
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP20020007A2 publication Critical patent/HRP20020007A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20020007A 1999-07-12 2000-07-06 Vitamin d3 analogs HRP20020007A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14341399P 1999-07-12 1999-07-12
PCT/EP2000/006393 WO2001004089A1 (en) 1999-07-12 2000-07-06 Vitamin d3 analogs

Publications (1)

Publication Number Publication Date
HRP20020007A2 true HRP20020007A2 (en) 2003-04-30

Family

ID=22503954

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020007A HRP20020007A2 (en) 1999-07-12 2000-07-06 Vitamin d3 analogs

Country Status (36)

Country Link
US (1) US6331642B1 (pl)
EP (1) EP1200399B1 (pl)
JP (1) JP3803579B2 (pl)
KR (1) KR100477161B1 (pl)
CN (1) CN1174964C (pl)
AR (1) AR024695A1 (pl)
AT (1) ATE262508T1 (pl)
AU (1) AU779408B2 (pl)
BR (1) BR0012419A (pl)
CA (1) CA2378803C (pl)
CO (1) CO5190683A1 (pl)
DE (1) DE60009303T2 (pl)
DK (1) DK1200399T3 (pl)
EG (1) EG23909A (pl)
ES (1) ES2215707T3 (pl)
GC (1) GC0000198A (pl)
HK (1) HK1047578B (pl)
HR (1) HRP20020007A2 (pl)
HU (1) HUP0202157A3 (pl)
IL (2) IL147254A0 (pl)
JO (1) JO2255B1 (pl)
MA (1) MA26808A1 (pl)
MX (1) MXPA02000313A (pl)
MY (1) MY122633A (pl)
NO (1) NO20020161D0 (pl)
NZ (1) NZ516339A (pl)
PE (1) PE20010328A1 (pl)
PL (1) PL201877B1 (pl)
PT (1) PT1200399E (pl)
RS (1) RS50229B (pl)
RU (1) RU2235721C2 (pl)
TR (1) TR200200054T2 (pl)
TW (1) TWI268276B (pl)
UY (1) UY26239A1 (pl)
WO (1) WO2001004089A1 (pl)
ZA (1) ZA200110487B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013832A1 (fr) * 2000-08-17 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Agent therapeutique destine au traitement de l'osteoporose
AU2001296542B2 (en) 2000-10-02 2007-10-25 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
EP1430026A1 (en) * 2001-09-21 2004-06-23 F. Hoffmann-La Roche Ag 3-desoxy-vitamin d3 analog esters
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CA2524026A1 (en) * 2003-04-30 2004-11-18 Bioxell S.P.A. Gemini vitamin d3 compounds and methods of use thereof
US20050113348A1 (en) * 2003-06-12 2005-05-26 Yanchun Li Vitamin D and vitamin D analogs or derivatives as new anti-hypertensive agents
US7332482B2 (en) * 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
JP2007506780A (ja) * 2003-09-24 2007-03-22 ビオエクセル エスピーエー 膀胱機能障害の治療方法
GB2407499B (en) * 2003-11-03 2008-02-27 Bioxell Spa Vitamin D3 analogue for use in the treatment of BPH
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
EP1797033A4 (en) * 2004-09-24 2010-04-28 Bioxell Spa 20-CYCLOALKYL-26,27-ALKYL / HALOGENALKYL-VITAMIN-D3 COMPOUNDS AND METHODS FOR THEIR APPLICATION
CA2586679A1 (en) 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
ES2544819T3 (es) * 2007-05-30 2015-09-04 Opko IP Holdings II, Inc. Proceso para la producción de precursores de la vitamina D de óxido de fosfina
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
EP2682386B1 (en) * 2011-03-02 2016-08-17 Nihon University Novel vitamin d receptor modulator with partial agonist activity
KR102523660B1 (ko) 2016-09-26 2023-04-19 (주)하이플 박스용 테두리 부재보강부재와 에셈블리컨테이너 원터치크립이 포함된 박스

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749710A (en) 1985-05-01 1988-06-07 Hoffmann-La Roche Inc. Immunosuppressive agents
ZA8923B (en) * 1988-01-20 1989-09-27 Hoffmann La Roche 16-dehydro-vitamin d3-derivatives
US5087619A (en) * 1988-01-20 1992-02-11 Hoffman-La Roche Inc. Vitamin D3 analogs
CA2096105A1 (en) * 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
US5401733A (en) * 1993-10-01 1995-03-28 Hoffmann-La Roche Inc. Stable and active metabolites of 1,25-dihydroxy-16-ene-cholecalciferol
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
US6040300A (en) * 1995-04-07 2000-03-21 Arch Development Corporation Method of preventing colon cancer with vitamin D3 analogues
AU708679B2 (en) 1996-03-21 1999-08-12 F. Hoffmann-La Roche Ag 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives

Also Published As

Publication number Publication date
CN1174964C (zh) 2004-11-10
KR100477161B1 (ko) 2005-03-18
TWI268276B (en) 2006-12-11
YU92701A (sh) 2004-09-03
EP1200399A1 (en) 2002-05-02
NO20020161L (no) 2002-01-11
ZA200110487B (en) 2003-03-20
PT1200399E (pt) 2004-06-30
KR20020033728A (ko) 2002-05-07
JP2003504354A (ja) 2003-02-04
DE60009303D1 (de) 2004-04-29
AR024695A1 (es) 2002-10-23
WO2001004089A1 (en) 2001-01-18
JO2255B1 (en) 2004-10-07
HK1047578B (zh) 2005-04-29
CN1360572A (zh) 2002-07-24
JP3803579B2 (ja) 2006-08-02
US6331642B1 (en) 2001-12-18
HUP0202157A2 (en) 2002-10-28
PL201877B1 (pl) 2009-05-29
PE20010328A1 (es) 2001-03-22
TR200200054T2 (tr) 2002-06-21
NZ516339A (en) 2003-07-25
NO20020161D0 (no) 2002-01-11
HUP0202157A3 (en) 2004-04-28
PL356124A1 (pl) 2004-06-14
AU6689400A (en) 2001-01-30
IL147254A0 (en) 2002-08-14
GC0000198A (en) 2006-03-29
MXPA02000313A (es) 2002-06-21
EP1200399B1 (en) 2004-03-24
ATE262508T1 (de) 2004-04-15
CA2378803C (en) 2009-01-27
ES2215707T3 (es) 2004-10-16
RS50229B (sr) 2009-07-15
RU2235721C2 (ru) 2004-09-10
HK1047578A1 (en) 2003-02-28
AU779408B2 (en) 2005-01-20
UY26239A1 (es) 2000-10-31
CO5190683A1 (es) 2002-08-29
EG23909A (en) 2007-12-30
BR0012419A (pt) 2002-03-26
MA26808A1 (fr) 2004-12-20
IL147254A (en) 2006-07-05
MY122633A (en) 2006-04-29
DK1200399T3 (da) 2004-07-19
CA2378803A1 (en) 2001-01-18
DE60009303T2 (de) 2005-02-24

Similar Documents

Publication Publication Date Title
US5612328A (en) Vitamin D3 fluorinated analogs
RU2134260C1 (ru) Аналоги витамина d3, способ их получения и фармацевтический препарат
HRP20020007A2 (en) Vitamin d3 analogs
RU2136660C1 (ru) Аналоги витамина d, способы их получения и фармацевтическая композиция
US5753638A (en) Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs
RU2165923C2 (ru) Аналоги витамина d, способ их получения, фармацевтическая композиция
JPH09511224A (ja) ビタミンｄアミンおよびアミド誘導体
FI112323B (fi) 1alfa-fluori-25-hydroksi-16-eeni-23-yynikolekalsiferolin uusi käyttö
ES2404061T3 (es) 2-Metileno-19-nor-(20S-24S)-1-alfa,25-dihidroxivitamina-D2
KR20050120787A (ko) 2-프로필리덴-19-노르-비타민 ｄ 화합물
JP2008520709A (ja) ２−メチレン−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−トリスホモプレグナカルシフェロール
RU2175318C2 (ru) Производные витамина d3, способы его получения, фармацевтическая композиция
JP2008520708A (ja) ２−メチレン−１９−ノル−（２０Ｒ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
JP2008538214A (ja) ２−メチレン−１９−ノル−（２３Ｓ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトンおよび２−メチレン−１９−ノル−（２３Ｒ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトン
US4929609A (en) 25, 28-dihydroxyergocalciferol and 1,25,28-trihydroxyergocalciferol compositions thereof and their use in the treatment of hyperproliferative disease
JP2801587B2 (ja) １，２５−ジヒドロキシ−１６，２２，２３−トリスデヒドロ−コレカルシフェロール誘導体
CA2588063C (en) 2-methylene-19,21-dinor-1.alpha.-hydroxy-bishomopregnacalciferol
US5840718A (en) 22-epimeric-1,25-dihydroxy-16,22,23-triene-cholecalciferol
JPH10512297A (ja) ２４−ホモ−２６，２７−ヘキサフルオロ−コレカルシフェロール類

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODBC Application rejected